The very low fasting plasma C-peptide level at baseline before CT in the late therapy patients, compared with the early therapy patients, reflects the progressive loss of islet β-cell function that occurs over months without therapy, other than insulin, in patients with T1D (18). This evidence concerns the gene INS and type 1 diabetes mellitus.